MYD88 and diffuse large B-cell lymphoma: For instance, in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM), proteins such as CD79 and MyD88 trigger NFκB activation through gain-of-function mutations [45, 46].